F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 4, 2017, Pages 678-688

  Giesel, Frederik L ^a   Hadaschik, B ^a   Cardinale, J ^b   Radtke, J ^a   Vinsensia, M ^a   Lehnert, W ^c   Kesch, C ^a   Tolstov, Y ^a   Singer, S ^a   Grabe, N ^a,d   Duensing, S ^a   Schafer M ^b   Neels, O C ^b   Mier, W ^a   Haberkorn, U ^a   Kopka, K ^b   Kratochwil, C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c ABX CRO   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

18F PSMA; F 18 PSMA; PET CT; Positron emission tomography; PSMA 1007

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN 1007 F 18; TRACER; UNCLASSIFIED DRUG; FLUORINE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG HALF LIFE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSTATE CANCER; PROSTATECTOMY; RENAL CLEARANCE; VALIDATION STUDY; WHOLE BODY PET; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY; PROSTATE TUMOR; RADIATION DOSE; TISSUE DISTRIBUTION; URINARY EXCRETION;

AGED; ANTIGENS, SURFACE; FLUORINE RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RENAL ELIMINATION; TISSUE DISTRIBUTION;

EID: 84997109073     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-016-3573-4     Document Type: Article

References (33)

1. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209. doi:10.1007/s00259-014-2949-6.
2. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74. doi:10.2967/jnumed.115.154153.
3. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56(8):1185–90. doi:10.2967/jnumed.115.160382.
4. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. doi:10.1007/s00259-013-2525-5.
5. Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, et al. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol. 2016;11(1):73. doi:10.1186/s13014-016-0646-2.
6. Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43(1):34–41. doi:10.1007/s00259-015-3188-1.
7. Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016. doi:10.1016/j.eururo.2015.12.053.
8. Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz H, Schrader A, et al. Correlation of intraprostatic tumor extent with 68-Ga-PSMA distribution in patients with prostate cancer. J Nucl Med. 2016. doi:10.2967/jnumed.115.169243.
9. Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, et al. Intra-individual comparison of 68Ga-PSMA11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(8):1400–6. doi:10.1007/s00259-016-3346-0.
10. Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, et al. 68Ga-PSMA-HBED-CC PET/CT detects location and extent of primary prostate cancer. J Nucl Med. 2016.
11. Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014;55(11):1791–8. doi:10.2967/jnumed.114.140426.
12. Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55–62. doi:10.1016/j.apradiso.2012.06.034.
13. Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53(12):1883–91. doi:10.2967/jnumed.112.104661.
14. Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565–74. doi:10.1007/s11307-015-0850-8.
15. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016;57(8):1170–6. doi:10.2967/jnumed.115.171397.
16. Ahmadzadehfar H, Eppard E, Kürpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477–88.
17. Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016.
18. 18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43(10):1929–30. doi:10.1007/s00259-016-3447-9.
19. Benešová M, Bauder-Wüst U, Schäfer M, et al. Linker modification strategies to control the Prostate-Specific Membrane Antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J Med Chem. 2015;59:1761–75.
20. Olberg DE, Arukwe JM, Grace D, et al. One step radiosynthesis of 6-[18F]Fluoronicotinic Acid 2,3,5,6-Tetraflourophenyl Ester ([18F]-F-Py-TFP): a new prosthetic group for the efficient labeling of biomolecules with fluorine-18. J Med Chem. 2010;53:1732–40.
21. Cardinale J, Schäfer M, Benešová M, et al. Preclinical evaluation of 18F-PSMA-1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med. 2016. doi:10.2967/jnumed.116.181768.
22. Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non–marrow-targeting 90Y-antibody therapy. J Nucl Med. 2002;43:1245–53.
23. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689–94.
24. Andersson M, Johansson L, Minarik D, Mattsson S, Leide-Svegborn S. An internal radiation dosimetry computer program, IDAC2.0, for estimation of patient dose for radiopharmaceuticals. Radiat Prot Dosim. 2013;162(3):299–305.
25. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023–7.
26. Stabin MG, Konijnenberg M. Re-evaluation of absorbed fractions for photons and electrons in small spheres. J Nucl Med. 2000;41:149–60.
27. ICRP: basic anatomical and physiological data for use in radiological protection reference values. ICRP Publication 89. Ann. ICRP. 2002; 32 (3–4): 1–277.
28. van der Kwast TH, Amin MB, Billis A, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 2011;24:16–25.
29. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–95. doi:10.1007/s00259-012-2298-2.
30. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697–705. doi:10.2967/jnumed.115.161299.
31. 68Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016.
32. Afshar-Oromieh A, Hetzheim H, Kübler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43(9):1611–20. doi:10.1007/s00259-016-3419-0.
33. Budäus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393–6. doi:10.1016/j.eururo.2015.06.010.